Core Viewpoint - The company announced that its subsidiary, Guangzhou Taihe Oncology Hospital Proton Therapy Center, has officially operated for one year since December 16, 2024, emphasizing its commitment to enhancing clinical capabilities and international collaboration in proton therapy [1] Group 1: Operational Performance - The Guangzhou Proton Therapy Center has fully utilized its four treatment rooms, providing proton therapy services to a total of 550 patients, with over 80 new patients added each month [1] - The center's patient demographic spans across 31 provincial administrative regions in China and over 20 countries and regions, with patients ranging in age from 1 to 91 years old [1] - The center completed China's first proton therapy for choroidal malignant melanoma in July 2025, marking a significant milestone in its operational achievements [1] Group 2: Strategic Development - The company is focused on strengthening its core competitiveness in high-end medical services through continuous optimization of service processes and improvement of treatment efficiency [1] - The steady advancement of the proton therapy business has further enhanced the company's layout in the field of precision cancer treatment [1] - Future plans include ongoing enhancements in clinical capabilities and collaboration with advanced international medical institutions to keep pace with global developments in proton therapy technology [1]
美中嘉和(02453.HK)：广州医院质子中心临床服务能力已得到充分验证 各项运营指标表现良好